Where was the Saltikva Phase 2 study conducted?

The Saltikva Phase 2 study was conducted at a single site, the Segal Cancer Centre of the Jewish General Hospital in Montreal, Quebec, Canada, with Gerald Batist, MD as principal investigator. The study was approved by Health Canada and a local ethics board. It was run outside the United States at one center (S-1/A No. 3). Expanded-access patients were treated at other locations, including Israel.